Dysregulated STAT1-SOCS1 control of JAK2 promotes mammary luminal progenitor cell survival and drives ER??(+) tumorigenesis
| Autor: | Jessica M. Archambault, Szeman Ruby Chan, Kathleen C. F. Sheehan, Julie A. Allen, Silvia Lonardi, Theresa M. McDevitt, J M White, Cora D. Arthur, William Vermi, Robert D. Schreiber, Deepta Bhattacharya, Charles G. Rickert, M V Lorenzi, D C Allred |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Mammary gland
Mammary Neoplasms Animal Suppressor of Cytokine Signaling Proteins medicine.disease_cause Suppressor of Cytokine Signaling 1 Protein medicine Animals Progenitor cell STAT3 Molecular Biology Original Paper Janus kinase 2 biology Prolactin receptor Estrogen Receptor alpha Cell Biology Janus Kinase 2 STAT1 Transcription Factor medicine.anatomical_structure Neoplastic Stem Cells biology.protein Cancer research Female Signal transduction Carcinogenesis Estrogen receptor alpha |
| Popis: | We previously reported that STAT1 expression is frequently abrogated in human estrogen receptor-α-positive (ERα+) breast cancers and mice lacking STAT1 spontaneously develop ERα+ mammary tumors. However, the precise mechanism by which STAT1 suppresses mammary gland tumorigenesis has not been fully elucidated. Here we show that STAT1-deficient mammary epithelial cells (MECs) display persistent prolactin receptor (PrlR) signaling, resulting in activation of JAK2, STAT3 and STAT5A/5B, expansion of CD61+ luminal progenitor cells and development of ERα+ mammary tumors. A failure to upregulate SOCS1, a STAT1-induced inhibitor of JAK2, leads to unopposed oncogenic PrlR signaling in STAT1−/− MECs. Prophylactic use of a pharmacological JAK2 inhibitor restrains the proportion of luminal progenitors and prevents disease induction. Systemic inhibition of activated JAK2 induces tumor cell death and produces therapeutic regression of pre-existing endocrine-sensitive and refractory mammary tumors. Thus, STAT1 suppresses tumor formation in mammary glands by preventing the natural developmental function of a growth factor signaling pathway from becoming pro-oncogenic. In addition, targeted inhibition of JAK2 may have significant therapeutic potential in controlling ERα+ breast cancer in humans. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|